Uric acid relates to dopamine transporter availability in Parkinson's disease

Acta Neurologica Scandinavica

Volumn 131, Issue 2, 2015, Pages 127-131

  Moccia, M ^a   Pappata S ^b   Erro, R ^c,d   Picillo, M ^a   Vitale, C ^e,f   Amboni, M ^f   Longo, K ^f   Palladino, R ^a,g   Barone, P ^h   Pellecchia, Maria Teresa ^h  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^f Neurology   (Italy)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF SALERNO   (Italy)

Author keywords

Biomarkers; Dopamine transporter; Parkinson's disease; SPECT; Urate; Uric; Uric acid

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE I 123; URIC ACID; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; BIOLOGICAL MARKER; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; URIC ACID BLOOD LEVEL; AGED; BLOOD; DIAGNOSTIC USE; EARLY DIAGNOSIS; METABOLISM; PROCEDURES; SCINTISCANNING;

ADULT; AGED; BIOLOGICAL MARKERS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; URIC ACID;

EID: 84922750415     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12295     Document Type: Article

References (16)

1. Gerlach M, Maetzler W, Broich K et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012;119:39-52.
2. Alonso A, Rodríguez LA, Logroscino G, Hernán MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696-700.
3. Ascherio A, Lewitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-8.
4. Schwarzschild MA, Schwid SR, Marek K et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716-23.
5. Constantinescu R, Andreasson U, Holmberg B, Zetterberg H. Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. Acta Neurol Scand 2013;127:e8-12.
6. Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord 2008;23:1653-7.
7. Kumral E, Karaman B, Orman M, Kabaroglu C. Association of uric acid and carotid artery disease in patients with ischemic stroke. Acta Neurol Scand 2014;130:11-7.
8. Schwarzschild MA, Marek K, Eberly S et al. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord 2011;26:1864-8.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
10. Fahn S, Elton RL, UPDRS Program Members. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987; 153-63.
11. Varrone A, Pellecchia MT, Amboni M et al. Imaging of dopaminergic dysfunction with 123I-FP-CIT SPECT in early-onset parkin disease. Neurology 2004;63:2097-103.
12. Scherfler C, Schwarz J, Antonini A et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22:1229-38.
13. Ravina B, Marek K, Eberly S et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012;27:1392-7.
14. Nissen T, Malek N, Grosset KA et al. Baseline [(123) I]FP-CITSPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease. Acta Neurol Scand 2014;129:204-8.
15. Contrafatto D, Mostile G, Nicoletti A et al. [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. Acta Neurol Scand 2012;126:12-6.
16. Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141-50.